stockrow
Saturday 7 November 2026
Export SLDB’s income statement to Excel — free account
Solid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million.
- EPS
- +25.6%
- Free cash flow
- −39.6%
Quarter to September 2026, against a year earlier
6.57
0.39
+6.31%
Follow SLDB
Alert me
Solid Biosciences Inc. (SLDB) P/E ratio
Solid Biosciences Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DNA Ginkgo Bioworks Holdings, Inc. compare | n/m |
| SANA Sana Biotechnology, Inc. compare | n/m |
| SLDB Solid Biosciences Inc. | n/m |
| ACHV Achieve Life Sciences, Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| ATTO Attovia Therapeutics, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)